相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma
Ivan Pourmir et al.
WORLD JOURNAL OF UROLOGY (2021)
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Audrey Simonaggio et al.
CANCERS (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
Elif Hindie
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
Mary A. Wood et al.
GENOME MEDICINE (2020)
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Matthew Kyle Labriola et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard et al.
BULLETIN DU CANCER (2020)
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J. Motzer et al.
CANCER (2020)
Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naive metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Y. Vano et al.
ANNALS OF ONCOLOGY (2020)
Radiation Therapy for Patients with Advanced Renal Cell Carcinoma
Joseph A. Miccio et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer et al.
NATURE MEDICINE (2020)
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Matthew D. Tucker et al.
CANCERS (2020)
A new dawn for eosinophils in the tumour microenvironment
Sharon Grisaru-Tal et al.
NATURE REVIEWS CANCER (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Opposing roles of eosinophils in cancer
Sonja C. S. Simon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A. Ari Hakimi et al.
CANCER DISCOVERY (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian Rini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Alvaro Moreira et al.
IMMUNOTHERAPY (2017)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
Hong-Kai Wang et al.
ONCOTARGET (2016)
Predictive immune markers in advanced melanoma patients treated with ipilimumab
Viktor Umansky et al.
ONCOIMMUNOLOGY (2016)
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
Rafael Carretero et al.
NATURE IMMUNOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Radiotherapy for renal-cell carcinoma
Gert De Meerleer et al.
LANCET ONCOLOGY (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Involvement of eosinophils in the anti-tumor response
Solene Gatault et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Peripheral blood eosinophil count correlates with survival in lung cancer
A. Shelton et al.
LUNG CANCER (2010)
Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance
Ljubov Simson et al.
JOURNAL OF IMMUNOLOGY (2007)
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs) - Role in the inflammatory response within tumors
Ramin Lotfi et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response
Stephania A. Cormier et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
分享论文
